Abstract 469P
Background
The advancements in treatment strategies for cancer in Adolescent and Young Adults (AYAs) and early diagnosis has led to an increase in the cure rate and an increase in the number of AYA cancer survivors. The AYA patient is defined as an individual 15 to 39 years of age at the time of initial cancer diagnosis. AYA cancer survivors are at increased risk of developing various physical and psychosocial issues which vary from those in older adults. There are very few integrated survivorship programmes for AYA cancer survivors in India and this is a huge unmet need.
Methods
This online survey was directed at oncologists from various major specialties in India, with an interest in the care of AYA cancer patients and survivors. Oncologists practicing in India were sent the survey questionnaire through Google link via e-mail. Data was collected in SPSS and descriptive statistics were performed.
Results
We received 100 responses from June 2021 to September 2021 from oncologists all over India. 85% of respondents were medical oncologists, with 59% working at academic centers. Among oncologists who responded to this survey, 74% reported that AYA cancer survivors comprised ≤ 25% of their clinical practice. Major issues faced by most of the survivors included fatigue, anxiety, depression, fear of recurrence, and financial and social issues. Although 88% of the respondents reported the need for a separate follow-up clinic for AYA survivors, only 32% had a dedicated cancer survivor clinic or program at their center. Half of these oncologists had a team of multidisciplinary care providers in their clinic. 58% of the respondents reported that more than 50% of the survivors have resumed their normal life.
Conclusions
There is an unmet need for specialized care for AYA cancer survivors in India. Only 32% of oncologists have dedicated clinics for AYA cancer survivors. There is a need to develop survivorship programs for AYA survivors across the country.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract